

The rationale and design of the LATTEE registry – the first multicenter project on the Scientific Platform of the “Club 30” of the Polish Cardiac Society

Agnieszka Kapłon-Cieślicka^{1,2}, Monika Budnik^{1,2}, Monika Gawałko², Maciej Wójcik^{1,3}, Robert Błaszczuk³, Beata Uziębło-Życzkowska⁴, Paweł Krzeziński^{1,4}, Katarzyna Starzyk^{5,6}, Iwona Gorczyca^{5,6}, Anna Szymańska^{1,7}, Mirosław Dłużniewski⁷, Ludmiła Daniłowicz-Szymanowicz⁸, Damian Kaufmann⁸, Magdalena Mizia-Szubryt^{9,10}, Maciej T. Wybraniec^{1,9,10}, Maciej Haberk^{1,11}, Michał Kucio¹⁰, Anna Tomaszuk-Kazberuk^{1,12}, Katarzyna Wilk¹², Paweł Burchardt^{1,13,14}, Kinga Gościńska-Bis^{1,15}, Jarosław Hiczkiewicz^{16,17}, Katarzyna Łojewska¹⁶, Marek Koziński^{1,18}, Błażej Michalski^{1,19}, Andrzej Tomaszewski³, Piotr Scisło², Janusz Kochanowski², Krzysztof J. Filipiak^{1,2}, Grzegorz Opolski²

1 “Club 30”, Polish Cardiac Society, Poland

2 1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland

3 Department of Cardiology, Medical University of Lublin, Lublin, Poland

4 Department of Cardiology and Internal Diseases, Military Institute of Medicine, Warsaw, Poland

5 1st Clinic of Cardiology and Electrotherapy, Świętokrzyskie Cardiology Centre, Kielce, Poland

6 Faculty of Medical and Health Sciences, Jan Kochanowski University, Kielce, Poland

7 Department of Heart Diseases, Postgraduate Medical School, Warsaw, Poland

8 Department of Cardiology and Electrotherapy, Medical University of Gdańsk, Gdańsk, Poland

9 1st Department of Cardiology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland

10 Leszek Giec Upper-Silesian Medical Centre of the Medical University of Silesia in Katowice, Katowice, Poland

11 Department of Cardiology, School of Health Sciences, Medical University of Silesia, Katowice, Poland

12 Department of Cardiology, Medical University of Białystok, Białystok, Poland

13 Department of Biology and Lipid Disorders, Poznan University of Medical Sciences, Poznań, Poland

14 Department of Cardiology, Józef Struś Hospital, Poznań, Poland

15 Department of Electrocardiology, Leszek Giec Upper-Silesian Medical Centre of the Medical University of Silesia in Katowice, Katowice, Poland

16 Clinical Department of Cardiology, Nowa Sól Multidisciplinary Hospital, Nowa Sól, Poland

17 University of Zielona Góra, Zielona Góra, Poland

18 Department of Cardiology and Internal Medicine, Medical University of Gdańsk, Gdynia, Poland

19 Department of Cardiology, Władysław Biegański Hospital, Medical University of Lodz, Łódź, Poland

Correspondence to:

Agnieszka Kapłon-Cieślicka, MD, PhD, 1st Chair and Department of Cardiology, Medical University of Warsaw, ul. Banacha 1a, 02-097 Warszawa, Poland, phone: +48 22 599 29 58, email: agnieszka.kaplon@gmail.com

Received: August 5, 2019.

Revision accepted:

October 4, 2019.

Published online:

October 4, 2019.

Kardiologia Pol. 2019;

77 (11): 1078-1080

doi:10.33963/KP.15011

Copyright by the Author(s), 2019

Introduction Since its establishment 25 years ago, the “Club 30” of the Polish Cardiac Society has gathered young Polish scientists with meaningful achievements in cardiology.¹ The “Club 30” Scientific Platform has been created to facilitate initiation of and participation in multicenter studies among its users, and to promote integration of scientific community.² Multicenter cooperation, empowered by the platform, results in an increase in the number of enrolled patients and, consequently, enhances research quality and chances for publication in high-profile journals.

In patients with atrial fibrillation (AF) and atrial flutter (AFL), oral anticoagulation (OAC) reduces

the risk of both left atrial (LA) thrombus and ischemic stroke.³⁻⁵ Yet, some patients develop LA thrombus and experience thromboembolic events despite OAC.⁶⁻⁹ The CHA₂DS₂-VASc-RAF (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, history of stroke or thromboembolism, vascular disease, age 65 to 74 years, female sex, renal dysfunction, type of AF) score has been recently proposed to improve LA thrombus prediction in AF.⁹

The aim of the study is to assess the prevalence of LA thrombus in real-world patients with AF or AFL referred for transesophageal echocardiography (TEE), to identify predictors

of LA thrombus in these patients, and to validate the CHA₂DS₂-VASc-RAF score.

Methods The LATTEE registry (Left Atrial Thrombus on Transesophageal Echocardiography; ClinicalTrials.gov identifier, NCT03591627) is an ongoing multicenter prospective observational study, conducted in 13 Polish cardiology centers. The registry includes all consecutive patients with AF or AFL hospitalized in a participating center during the study period, who were scheduled for catheter ablation or cardioversion for AF or AFL and had TEE performed prior to the procedure (irrespective of whether the procedure was finally carried out or not). The exclusion criteria are age below 18 years and inconclusive TEE results regarding the presence of LA thrombus. Patients are enrolled in the study irrespective of the presence or type of OAC. Each of the 13 participating centers will include at least 200 patients. Thus, the total number of patients in the registry is estimated to exceed 2600. In each participating center, recruitment will last 12 months, starting from the date of enrollment of the first patient in this center, or longer if the required number of 200 patients is not reached by the participating center within 12 months.

In all patients, data on clinical characteristics, pharmacotherapy, routine blood tests, and TEE results are collected. All other tests are performed at the discretion of the attending physician within the standards of care in a given center. However, if available, data from

transthoracic echocardiography and Holter monitoring are also recorded (TABLE 1). If a patient undergoes repeated TEE during the study (eg, before another procedure or a control TEE for LA thrombus), this is also reported in the registry (separately for a given patient), together with data on the current antithrombotic treatment.

The primary endpoint of the study is the presence of LA thrombus on TEE.

The study was approved by the Ethics Committee of the Medical University of Warsaw (AKBE/113/2018). The Ethics Committee waived the requirement of obtaining informed consent from the patients.

Statistical analysis The proportion of patients undergoing ablation to those undergoing cardioversion, as well as patients' clinical characteristics and thromboembolic risk, may vary between participating centers depending on their individual profiles. Still, it may be anticipated that approximately 85% to 90% of enrolled patients will receive OAC. In OAC-treated populations, the prevalence of LA thrombus ranges from 1% to 10%.⁸⁻¹² If the registry includes a total of 2600 patients, over 100 cases of LA thrombus are anticipated, providing an adequate number of study endpoints for a logistic regression analysis of the predictors of LA thrombus. Receiver operating characteristic curves will be constructed and areas under the curve calculated to assess the prognostic accuracy of the CHA₂DS₂-VASc-RAF score (in comparison with other models) for the identification

TABLE 1 Laboratory data collected in the LATTEE registry

Test	Data
In all patients	
Blood tests	Complete blood count Creatinine, GFR Alanine and aspartate aminotransferases INR, APTT
TEE	Presence of LA thrombus Location of LA thrombus (LAA vs LA cavity) Presence of SEC, including dense SEC LAA emptying velocity (in relation to rhythm during TEE)
If available	
TEE	LAA morphology (windsock, chicken wing, cactus, or cauliflower)
Transthoracic echocardiography	Left ventricular ejection fraction (Ap4Ch/Ap2Ch) LA dimension (PLAX) LA area (Ap4Ch) LAVI (Ap4Ch/Ap2Ch)
Holter monitoring	Presence of AF or AFL AF or AFL burden

Abbreviations: AF, atrial fibrillation; AFL, atrial flutter; APTT, activated partial thromboplastin time; Ap2Ch, apical 2-chamber view; Ap4Ch, apical 4-chamber view; GFR, glomerular filtration rate; INR, international normalized ratio; LA, left atrial; LAA, left atrial appendage; LAVI, left atrial volume index; PLAX, parasternal long-axis view; SEC, spontaneous echo contrast; TEE, transesophageal echocardiography

of patients with LA thrombus. Analyses will be performed using the SAS software, version 9.2 (SAS Institute, Cary, North Carolina, United States).

Discussion The CHA₂DS₂-VAsC score is a recommended tool for thromboembolic risk stratification in AF and AFL.³ Still, it may not encompass all clinically relevant predictors of LA thrombus formation.^{6,7,13-15} The type of AF has long been perceived as irrelevant for thromboembolic risk assessment. However, recently, nonparoxysmal AF has been shown to be independently associated with a higher risk of thromboembolic events than paroxysmal AF.^{6,7,9} Moreover, in paroxysmal AF, evaluation of AF burden might improve thromboembolic risk stratification.¹⁴ Renal dysfunction is another variable found to be a strong predictor of stroke and systemic embolism that is not included in the CHA₂DS₂-VAsC score.¹⁵

Recently, a new CHA₂DS₂-VAsC-based model, namely, the CHA₂DS₂-VAsC-RAF score (R for renal dysfunction, AF for AF type), has proved superior to both the CHADS₂ and CHA₂DS₂-VAsC scores in identifying patients with LA thrombus.⁹ The primary goal of the LATTEE registry is to validate, and possibly recalibrate, the CHA₂DS₂-VAsC-RAF score. Secondary analyses will include evaluation of LA thrombus risk in patients on different OAC regimens, depending on LA appendage (LAA) morphology, as well as in various predefined subgroups, including patients with heart failure, aortic stenosis, mitral regurgitation, diabetes, chronic kidney disease, men vs women, and elderly population.

The main limitation of the LATTEE registry is the use of a surrogate endpoint of LA thrombus and not ischemic stroke. However, LA thromboembolism represents the primary mechanism involved in the etiopathology of ischemic stroke in AF. Thus, we believe that the presence of LA thrombus on TEE may be considered an adequate surrogate endpoint. Another limitation, resulting from the study methodology (inclusion of patients referred for TEE), is that its participants—scheduled for ablation or cardioversion—can be expected to have lower thromboembolic risk than the general AF population. However, the identification of additional novel risk factors for LAA thrombus formation seems to be particularly valuable in patients with presumed low or intermediate thromboembolic risk (who will be adequately represented in the LATTEE registry) as opposed to those who are already known to be at high thromboembolic risk. Finally, it would be ideal to record all TEE studies and verify the presence of LA thrombus centrally in a core laboratory. However, this has not been undertaken in our registry.

In conclusion, the LATTEE registry is the largest study of patients with AF or AFL undergoing TEE in Poland. It will investigate the prognostic accuracy of the CHA₂DS₂-VAsC-RAF score. It will also provide information on the residual risk of

LA thrombus in patients treated with OAC and in different AF subpopulations. A significant number of centers participating in the LATTEE registry proves the utility of the “Club 30” Scientific Platform and reflects the will for integration of the young Polish scientific community.

ARTICLE INFORMATION

ACKNOWLEDGMENTS The LATTEE registry was initiated on the “Club 30” Scientific Platform of the Polish Cardiac Society.

The LATTEE registry does not receive any funding. The “Club 30” Scientific Platform was designed and created by the Members of the 2017–2019 Board of “Club 30.” The Members did not receive any remuneration. The only costs of the “Club 30” Scientific Platform were remuneration for the programmer and costs of the server provider, which were covered by “Club 30.”

Investigators other than those listed as Authors include Dagmara Wojtowicz (Gdańsk); Renata Wachnicka-Truty (Gdynia); Jolanta Pol-Romik, Krzysztof S. Golba (Katowice); Agnieszka Woronowicz-Chróściel (Kielce); Konrad Pieszko, Jan Budzianowski, Bogdan Musielak (Nowa Sól).

CONFLICT OF INTEREST None declared.

OPEN ACCESS This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0), allowing third parties to download articles and share them with others, provided the original work is properly cited, not changed in any way, distributed under the same license, and used for non-commercial purposes only. For commercial use, please contact the journal office at kardiologiapolska@ptkardio.pl.

HOW TO CITE Kapłon-Cieślicka A, Budnik M, Gawałko M, et al. The rationale and design of the LATTEE registry – the first multicenter project on the Scientific Platform of the “Club 30” of the Polish Cardiac Society. *Kardiol Pol.* 2019; 77: 1078-1080. doi:10.33963/KP.15011

REFERENCES

- 1 Jankowska EA, Kalarus Z. ‘Club 30’: twenty-year anniversary. *Eur Heart J.* 2014; 35: 2499-2501.
- 2 “Club 30” Scientific Platform website. <https://platformklub30.ptkardio.pl>. Accessed August 5, 2019.
- 3 Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J.* 2016; 37: 2893-2962.
- 4 Grzešek G, Janiszewska E, Malinowski B, et al. Adherence in patients with atrial fibrillation treated with dabigatran. *Kardiol Pol.* 2018; 76: 1562-1563.
- 5 Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. *Kardiol Pol.* 2018; 76: 1283-1298.
- 6 Steinberg BA, Hellkamp AS, Lokhnygina Y, et al. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. *Eur Heart J.* 2015; 36: 288-296.
- 7 Ganesan AN, Chew DP, Hartshorne T, et al. The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis. *Eur Heart J.* 2016; 37: 1591-1602.
- 8 Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med.* 2009; 361: 1139-1151.
- 9 Kapłon-Cieślicka A, Budnik M, Gawałko M, et al. Atrial fibrillation type and renal dysfunction as important predictors of left atrial thrombus. *Heart.* 2019; 105: 1310-1315.
- 10 Niku AD, Shiota T, Siegel RJ, Rader F. Prevalence and resolution of left atrial thrombus in patients with nonvalvular atrial fibrillation and flutter with oral anticoagulation. *Am J Cardiol.* 2019; 123: 63-68.
- 11 Dorenkamp M, Sohns C, Vollmann D, et al. Detection of left atrial thrombus during routine diagnostic work-up prior to pulmonary vein isolation for atrial fibrillation: role of transesophageal echocardiography and multidetector computed tomography. *Int J Cardiol.* 2011; 163: 26-33.
- 12 Jia F, Tian Y, Lei S, et al. Incidence and predictors of left atrial thrombus in patients with atrial fibrillation prior to ablation in the real world of China. *Indian Pacing Electrophysiol J.* 2019; 19: 134-139.
- 13 Suo Y, Zhang Y, Wang Y, et al. Renin-angiotensin system inhibition is associated with reduced risk of left atrial appendage thrombus formation in patients with atrial fibrillation. *Cardiol J.* 2018; 25: 611-620.
- 14 Boriani G, Botto GL, Padeletti L, et al. Improving stroke risk stratification using the CHADS₂ and CHA₂DS₂-VAsC risk scores in patients with paroxysmal atrial fibrillation by continuous arrhythmia burden monitoring. *Stroke.* 2011; 42: 1768-1770.
- 15 Piccini JP, Stevens SR, Chang Y, et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AntiCoagulation and Risk factors In Atrial fibrillation) study cohorts. *Circulation.* 2013; 127: 224-232.